Previous 10 | Next 10 |
2024-01-25 08:08:18 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company Amneal Pharmaceuticals, Inc. (AMRX) Q3 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Pre...
MONTREAL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal"), granting Knigh...
- Fluorometholone Ophthalmic Suspension, USP, 0.1% - Product has 180-day competitive generic therapy exclusivity Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced the approval and launch of fluorometholone ophth...
More new product innovations in 2023, as compared to 26 in 2022 13 new products launched in the fourth quarter of 2023 Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) today announces that it has launched 39 new retail and injectable medicines in 2023, as compare...
Amneal Pharmaceuticals Inc. (AMRX) is expected to report $0.1 for Q3 2023
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the 42 nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. Chirag will present on January 10 ...
2023-12-15 16:09:17 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company Amneal Pharma in pact with Strides to launch generic Vascepa Amneal Pharmaceuticals Non-GAAP EPS of $0.19 beats by $0.06, revenue of $6...
- Nasdaq move will be effective on December 27, 2023 Amneal Pharmaceuticals, Inc. (“Amneal”) (NYSE: AMRX) today announced that it will transfer its stock exchange listing to the Nasdaq Stock Market (“Nasdaq”) from the New York Stock Exchange (“NYSEȁ...
2023-12-14 14:26:24 ET More on AbbVie, AstraZeneca, etc. GSK - Greenshoots In The Horizon AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca Is Feeling The Weight Of The Market In 2023 AbbVie, Amgen among firms targeted for latest Medi...
2023-12-09 22:23:45 ET Summary Amneal Pharmaceuticals' stock price has been on a strong bull run, now exceeding $5 per share, and up over >145% this year. The company experienced losses in 2018 and 2019 but has since seen improvements in revenues and net income, as the manageme...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NYSE Market:
Amneal Pharmaceuticals Inc. Class A Website:
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...
Builds on successful U.S. biosimilar partnership of 2 oncology products (RELEUKO ® & FYLNETRA ® ) ADL018 is Kashiv’s lead pipeline biosimilar program, currently in Phase III Kashiv BioSciences, LLC (“Kashiv” or the “Companyȁ...